AN2 Therapeutics, Inc. (Nasdaq: ANTX), a biopharmaceutical company advancing novel small molecule therapeutics derived from ...
AN2 Therapeutics Inc (NASDAQ:ANTX) has voluntarily paused Phase 3 enrollment in the Phase 2/3 trial (EBO-301) evaluating epetraborole in treatment-refractory Mycobacterium Avium Complex (MAC) lung ...
Avian tuberculosis, also known as mycobacterium avium complex (MAC) or MAC lung disease, is a respiratory illness. It can lead to symptoms such as chronic cough, shortness of breath, and weight loss.
MENLO PARK, Calif.--(BUSINESS WIRE)-- AN2 Therapeutics, Inc. (Nasdaq: ANTX), a clinical-stage biopharmaceutical company focused on developing treatments for rare, chronic, and serious infectious ...
Study authors shared late-breaking data in a session on clinical trial results in pulmonary medicine at the American Thoracic Society 2024 International Conference. Investigators shared late-breaking ...
Zacks Investment Research on MSN
INSM stock jumps on 2025 preliminary sales, 2026 goals announced
Shares of Insmed INSM gained more than 3% on Friday after the company reported preliminary sales numbers for full-year 2025.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback